Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Hidradenitis suppurativa promise sends Moonlake soaring
Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.